BioCentury
ARTICLE | Company News

Skyline Diagnostics, Trovagene deal

July 5, 2010 7:00 AM UTC

Skyline received a license to use TrovaGene's nucleophosmin ( NPM1; B23) technology in Skyline's AMLprofiler microarray in vitro diagnostic test for acute myelogenous leukemia (AML). NPM1 mutation st...